Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhou, Jianya ^a   Zhao, Jing ^b   Sun, Ke ^b   Wang, Bo ^b   Wang, Lijun ^b   Chen, Xi ^a   Zheng, Jing ^a   You, Qihan ^b   Wang, Xiaoling ^b   Ding, Wei ^b   Zhou, Jianying ^a  

^a College of Medicine   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANTIBODY DETECTION; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; CLINICAL TRIAL; ECONOMICS; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES;

ANAPLASTIC LYMPHOMA KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899842927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092828     Document Type: Article

References (22)

1. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703.
2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566. (Pubitemid 47206930)
3. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8:823-859.
4. Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, et al. (2013) Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: Implications for ALK inhibitor therapy. Cancer Sep 10. [Epub ahead of print]
5. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, et al. (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581-5590.
6. Palmer RH, Vernersson E, Grabbe C, Hallberg B. (2009) Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420:345-361.
7. Mano H. (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99:2349-2355.
8. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571.
9. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174:661-670.
10. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, et al. (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7:348-354.
11. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6:466-472.
12. Hofman P, Ilie M, Hofman V, Roux S, Valent A, et al. (2012) Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 23:1738-1743.
13. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, et al. (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8:45-51.
14. Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, et al. (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 15:341-346.
15. Ying J, Guo L, Qiu T, Shan L, Ling Y, et al. (2013) Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol Jul 31. [Epub ahead of print]
16. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F. (2011) Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 30:57.
17. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, et al. (2012) A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 7:e36-e38.
18. Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, et al. (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7:e14-e16.
19. Bavieri M, Tiseo M, Lantuejoul S, McLeer-Florin A, Lasagni A, et al. (2013) Fishing for ALK with immunohistochemistry may predict response to crizotinib. Tumori 99; 5:e229-232.
20. Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, et al. (2013) Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8:322-328.
21. Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, et al. (2012) Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 15; 118:4486-4494.
22. Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, et al. (2013) Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26; 12:154515-154553.